desloratadine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
histamine-H1 receptor antagonists, tricyclic compounds 814 100643-71-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • SCH-34117
  • SCH 34117
  • desloratadine
  • azomyr
  • delopedil
  • descarboethoxyloratadine
  • descarboethoxyloratidine
  • neoclarityn
major metabolite of loratadine
  • Molecular weight: 310.83
  • Formula: C19H19ClN2
  • CLOGP: 3.83
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 1
  • TPSA: 24.92
  • ALOGS: -4.90
  • ROTB: 0

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
5 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 5 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.23 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
fu (Fraction unbound in plasma) 0.15 % Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Approvals:

DateAgencyCompanyOrphan
Dec. 21, 2001 FDA MERCK SHARP DOHME

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Angioedema 179.66 12.58 128 16853 47837 63424204
Urticaria 100.57 12.58 168 16813 165634 63306407
Endocrine ophthalmopathy 74.46 12.58 20 16961 651 63471390
Nasal ulcer 68.21 12.58 25 16956 2279 63469762
Intentional overdose 61.60 12.58 87 16894 74065 63397976
Toxic shock syndrome 61.10 12.58 18 16963 824 63471217
Drug reaction with eosinophilia and systemic symptoms 58.87 12.58 58 16923 33778 63438263
Pruritus 53.94 12.58 215 16766 361238 63110803
Allergy test positive 52.75 12.58 15 16966 605 63471436
Erythema 52.55 12.58 133 16848 175618 63296423
Eyelid disorder 47.21 12.58 18 16963 1831 63470210
Hallucination, auditory 45.17 12.58 33 16948 12791 63459250
Toxic skin eruption 45.03 12.58 33 16948 12852 63459189
Hyponatraemia 44.78 12.58 95 16886 111805 63360236
Mean cell haemoglobin increased 42.29 12.58 19 16962 2924 63469117
Dermatitis bullous 42.08 12.58 27 16954 8481 63463560
Drug intolerance 40.43 12.58 16 16965 308645 63163396
Systemic lupus erythematosus 38.89 12.58 5 16976 208913 63263128
Haemangioma congenital 38.74 12.58 11 16970 441 63471600
Swelling of eyelid 37.93 12.58 18 16963 3138 63468903
Terminal dribbling 37.12 12.58 6 16975 11 63472030
Rheumatoid arthritis 36.96 12.58 11 16970 253808 63218233
Paranoia 36.55 12.58 28 16953 11651 63460390
Intentional self-injury 33.89 12.58 38 16943 25649 63446392
Cholestasis 32.92 12.58 40 16941 29394 63442647
Wound 32.68 12.58 3 16978 163260 63308781
Eczema 29.98 12.58 40 16941 32251 63439790
Drug ineffective 28.98 12.58 163 16818 1044602 62427439
Completed suicide 28.31 12.58 3 16978 145670 63326371
Cerebral thrombosis 27.80 12.58 12 16969 1679 63470362
Death 27.43 12.58 36 16945 374345 63097696
Face oedema 26.84 12.58 30 16951 20182 63451859
Dyslipidaemia 25.98 12.58 19 16962 7374 63464667
Therapeutic product effect decreased 25.30 12.58 10 16971 193177 63278864
Aggression 24.77 12.58 31 16950 23467 63448574
Oxalosis 24.44 12.58 5 16976 47 63471994
Type IV hypersensitivity reaction 24.44 12.58 13 16968 2885 63469156
Victim of chemical submission 24.38 12.58 8 16973 524 63471517
Hepatic cytolysis 24.20 12.58 25 16956 15382 63456659
Tooth injury 24 12.58 10 16971 1282 63470759
Gestational hypertension 23.70 12.58 12 16969 2405 63469636
Blood immunoglobulin E increased 23.58 12.58 14 16967 3835 63468206
Skin dystrophy 23.18 12.58 5 16976 62 63471979
Rash maculo-papular 22.96 12.58 35 16946 31861 63440180
Contraindicated product administered 22.93 12.58 15 16966 217633 63254408
Vitamin D decreased 22.51 12.58 20 16961 10222 63461819
Somnolence 22.45 12.58 101 16880 178584 63293457
Burn oral cavity 21.71 12.58 5 16976 85 63471956
Hyperkalaemia 21.64 12.58 46 16935 54157 63417884
Eye infection 21.45 12.58 21 16960 12124 63459917
Haemorrhagic erosive gastritis 21.22 12.58 7 16974 466 63471575
Acute kidney injury 20.81 12.58 131 16850 263284 63208757
Synovial cyst 20.25 12.58 19 16962 10414 63461627
Hepatocellular injury 19.64 12.58 30 16951 27351 63444690
Tongue oedema 18.92 12.58 13 16968 4573 63467468
Onycholysis 18.65 12.58 9 16972 1627 63470414
Swelling 18.63 12.58 28 16953 275350 63196691
Pain 18.63 12.58 119 16862 740509 62731532
Dermatitis exfoliative generalised 18.62 12.58 12 16969 3795 63468246
Arrhythmia 18.37 12.58 35 16946 38105 63433936
Hyperoxaluria 18.18 12.58 5 16976 178 63471863
Inflammatory bowel disease 18.16 12.58 12 16969 3961 63468080
Joint swelling 17.96 12.58 38 16943 327628 63144413
Pelvic pain 17.83 12.58 20 16961 13499 63458542
Abortion 17.74 12.58 10 16971 2486 63469555
Urticaria thermal 17.72 12.58 6 16975 433 63471608
Guttate psoriasis 17.46 12.58 6 16975 453 63471588
HLA-B*27 positive 17.41 12.58 5 16976 209 63471832
Myalgia 17.05 12.58 81 16900 146448 63325593
Flatulence 16.90 12.58 32 16949 34670 63437371
Psychotic disorder 16.82 12.58 27 16954 25685 63446356
Infection 16.80 12.58 22 16959 229151 63242890
Arthrodesis 16.67 12.58 10 16971 2791 63469250
Nightmare 16.64 12.58 23 16958 19171 63452870
Conjunctivitis allergic 16.52 12.58 7 16974 935 63471106
Drug dose titration not performed 16.45 12.58 6 16975 539 63471502
Urine oxalate increased 16.41 12.58 5 16976 257 63471784
Feeding disorder 16.33 12.58 19 16962 13343 63458698
Alopecia 16.21 12.58 42 16939 337494 63134547
Photosensitivity reaction 16.16 12.58 20 16961 14974 63457067
Arteriospasm coronary 15.79 12.58 11 16970 3957 63468084
Rash erythematous 15.74 12.58 35 16946 42475 63429566
Keratopathy 15.74 12.58 6 16975 610 63471431
Therapeutic product effect incomplete 15.52 12.58 7 16974 125049 63346992
Helicobacter infection 15.49 12.58 3 16978 92782 63379259
Subretinal haematoma 15.45 12.58 3 16978 21 63472020
Abortion spontaneous 15.43 12.58 37 16944 47158 63424883
Urticaria chronic 15.29 12.58 6 16975 659 63471382
Amnestic disorder 15.29 12.58 5 16976 324 63471717
Chronic spontaneous urticaria 15.14 12.58 7 16974 1150 63470891
Patent ductus arteriosus 15.11 12.58 11 16970 4239 63467802
Disease progression 15.03 12.58 7 16974 122751 63349290
Eosinophilia 15.02 12.58 24 16957 22732 63449309
Upper respiratory tract infection bacterial 14.99 12.58 4 16977 127 63471914
Intraocular haematoma 14.78 12.58 3 16978 27 63472014
Hypersensitivity pneumonitis 14.58 12.58 9 16972 2641 63469400
Pharyngeal oedema 14.30 12.58 18 16963 13703 63458338
Pericarditis 13.94 12.58 9 16972 131570 63340471
Linear IgA disease 13.64 12.58 7 16974 1444 63470597
Lip oedema 13.59 12.58 10 16971 3914 63468127
Systolic hypertension 13.55 12.58 5 16976 464 63471577
Pancoast's syndrome 13.38 12.58 3 16978 45 63471996
Metabolic acidosis 13.32 12.58 34 16947 45035 63427006
Nasal pruritus 13.30 12.58 5 16976 489 63471552
Anaphylactic shock 13.04 12.58 23 16958 23610 63448431
Eyelid erosion 12.97 12.58 3 16978 52 63471989
Skin disorder 12.90 12.58 26 16955 29481 63442560
Food intolerance 12.72 12.58 9 16972 3316 63468725
Coma 12.69 12.58 42 16939 64322 63407719
Synovitis 12.64 12.58 19 16962 186899 63285142

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Troponin T increased 55.44 14.04 21 8341 2350 34946219
Eosinophilia 54.03 14.04 47 8315 26175 34922394
Toxic skin eruption 52.10 14.04 33 8329 11352 34937217
Rash maculo-papular 46.89 14.04 45 8317 28406 34920163
Dermatitis bullous 44.55 14.04 25 8337 6897 34941672
Death 44.35 14.04 20 8342 398029 34550540
Hepatic haematoma 41.02 14.04 11 8351 399 34948170
N-terminal prohormone brain natriuretic peptide increased 39.17 14.04 17 8345 2698 34945871
Hyperkaliuria 38.21 14.04 8 8354 96 34948473
Xerosis 36.81 14.04 11 8351 593 34947976
Corneal abscess 35.47 14.04 6 8356 19 34948550
Intentional overdose 34.21 14.04 47 8315 43627 34904942
Urticaria 33.09 14.04 56 8306 62321 34886248
Electrocardiogram QT prolonged 31.96 14.04 44 8318 40908 34907661
Eczema 30.07 14.04 29 8333 18407 34930162
Pruritus 29.92 14.04 88 8274 141893 34806676
Rash pustular 28.10 14.04 17 8345 5391 34943178
Oral dysaesthesia 27.42 14.04 6 8356 90 34948479
Keratitis 27.37 14.04 11 8351 1440 34947129
Acute generalised exanthematous pustulosis 26.97 14.04 18 8344 6758 34941811
Angioedema 25.98 14.04 38 8324 37336 34911233
Miosis 25.72 14.04 20 8342 9515 34939054
Purpura 24.34 14.04 20 8342 10291 34938278
Blood immunoglobulin E decreased 24.28 14.04 5 8357 55 34948514
Prurigo 23.62 14.04 8 8354 647 34947922
Arrhythmia 22.87 14.04 35 8327 35773 34912796
Eyelid ptosis congenital 21.89 14.04 5 8357 92 34948477
Bulbar palsy 21.74 14.04 6 8356 243 34948326
Disease prodromal stage 21.44 14.04 4 8358 25 34948544
Oedema genital 21.34 14.04 7 8355 513 34948056
Cholangiocarcinoma 21.28 14.04 9 8353 1340 34947229
Type III immune complex mediated reaction 20.42 14.04 6 8356 305 34948264
Dermatitis psoriasiform 20.39 14.04 9 8353 1487 34947082
Dermatitis exfoliative 20.28 14.04 15 8347 6624 34941945
Rhabdomyolysis 20.19 14.04 48 8314 68115 34880454
Pemphigoid 18.78 14.04 16 8346 8650 34939919
Wrong product administered 18.46 14.04 13 8349 5321 34943248
Spermatic cord disorder 17.86 14.04 3 8359 9 34948560
Retinopathy 17.63 14.04 9 8353 2055 34946514
Hyperlipasaemia 17.53 14.04 6 8356 501 34948068
Myoglobin blood increased 17.00 14.04 10 8352 3013 34945556
Rhinitis allergic 16.91 14.04 10 8352 3040 34945529
Purulent pericarditis 16.04 14.04 3 8359 19 34948550
Hypertrophic cardiomyopathy 15.89 14.04 7 8355 1150 34947419
Intentional self-injury 15.88 14.04 18 8344 13753 34934816
Vasoplegia syndrome 15.58 14.04 8 8354 1848 34946721
Wrong patient received product 15.50 14.04 9 8353 2645 34945924
Cardiac pacemaker evaluation 15.46 14.04 4 8358 126 34948443
Troponin I increased 15.42 14.04 9 8353 2673 34945896
Ischaemic cerebral infarction 15.39 14.04 7 8355 1240 34947329
Rash erythematous 15.37 14.04 24 8338 24953 34923616
Neonatal pneumonia 15.31 14.04 4 8358 131 34948438
Cerebral venous thrombosis 15.21 14.04 6 8356 748 34947821
Vascular cognitive impairment 14.74 14.04 3 8359 31 34948538
Coma 14.43 14.04 33 8329 45645 34902924

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Angioedema 158.12 12.24 145 21599 75890 79646754
Urticaria 123.53 12.24 198 21546 185003 79537641
Pruritus 83.83 12.24 267 21477 394381 79328263
Toxic skin eruption 83.52 12.24 60 21684 22233 79700411
Dermatitis bullous 76.62 12.24 48 21696 14197 79708447
Endocrine ophthalmopathy 72.46 12.24 20 21724 708 79721936
Nasal ulcer 69.54 12.24 25 21719 2115 79720529
Eosinophilia 63.80 12.24 70 21674 45275 79677369
Rash maculo-papular 62.85 12.24 77 21667 56001 79666643
Eczema 60.91 12.24 65 21679 40753 79681891
Death 58.07 12.24 42 21702 566472 79156172
Intentional overdose 56.95 12.24 103 21641 105857 79616787
Allergy test positive 54.44 12.24 16 21728 712 79721932
Toxic shock syndrome 53.76 12.24 18 21726 1231 79721413
Erythema 46.32 12.24 150 21594 223140 79499504
Eyelid disorder 45.69 12.24 18 21726 1960 79720684
Troponin T increased 44.75 12.24 21 21723 3501 79719143
Hallucination, auditory 44.01 12.24 40 21704 20653 79701991
Drug reaction with eosinophilia and systemic symptoms 43.17 12.24 69 21675 64175 79658469
Completed suicide 40.02 12.24 9 21735 245758 79476886
Cholestasis 37.84 12.24 58 21686 52051 79670593
Arrhythmia 37.38 12.24 63 21681 61209 79661435
Swelling of eyelid 37.26 12.24 19 21725 3792 79718852
Terminal dribbling 37 12.24 6 21738 11 79722633
Hepatic cytolysis 36.61 12.24 41 21703 27110 79695534
Electrocardiogram QT prolonged 34.29 12.24 76 21668 90310 79632334
Face oedema 33.75 12.24 40 21704 28096 79694548
Rash erythematous 33.40 12.24 58 21686 57711 79664933
Aggression 33.24 12.24 54 21690 50904 79671740
Rheumatoid arthritis 33.21 12.24 8 21736 208462 79514182
Hyperkaliuria 32.89 12.24 8 21736 170 79722474
Mean cell haemoglobin increased 32.40 12.24 18 21726 4267 79718377
Hyponatraemia 32.04 12.24 114 21630 177734 79544910
Drug intolerance 32.02 12.24 16 21728 264103 79458541
Hepatic haematoma 31.56 12.24 11 21733 850 79721794
Blood immunoglobulin E increased 29.58 12.24 19 21725 5863 79716781
Somnolence 29.34 12.24 136 21608 238845 79483799
Corneal abscess 29.15 12.24 6 21738 57 79722587
Oral dysaesthesia 27.01 12.24 7 21737 194 79722450
Acute generalised exanthematous pustulosis 26.66 12.24 28 21716 17226 79705418
Cerebral thrombosis 26.58 12.24 13 21731 2374 79720270
Gestational hypertension 26.36 12.24 12 21732 1867 79720777
Paranoia 25.61 12.24 29 21715 19403 79703241
N-terminal prohormone brain natriuretic peptide increased 25.51 12.24 16 21728 4739 79717905
Hepatocellular injury 25.21 12.24 46 21698 47547 79675097
Xerosis 24.48 12.24 10 21734 1196 79721448
Coma 23.98 12.24 71 21673 100578 79622066
Victim of chemical submission 23.91 12.24 8 21736 546 79722098
Nightmare 23.47 12.24 32 21712 25829 79696815
Prurigo 23.26 12.24 10 21734 1359 79721285
Oedema genital 23.21 12.24 8 21736 598 79722046
Abortion 22.97 12.24 10 21734 1400 79721244
Burn oral cavity 22.58 12.24 5 21739 69 79722575
Type IV hypersensitivity reaction 22.57 12.24 14 21730 4067 79718577
Synovial cyst 22.47 12.24 20 21724 10045 79712599
Acute kidney injury 22.36 12.24 228 21516 519176 79203468
Skin dystrophy 22.26 12.24 5 21739 74 79722570
Therapeutic product effect incomplete 21.48 12.24 6 21738 141639 79581005
Vitamin D decreased 21.07 12.24 19 21725 9706 79712938
Platelet count decreased 20.46 12.24 14 21730 194650 79527994
Bulbar palsy 20.39 12.24 6 21738 268 79722376
Oxalosis 20.39 12.24 5 21739 110 79722534
HLA-B*27 positive 20.35 12.24 5 21739 111 79722533
Hyperkalaemia 20.30 12.24 73 21671 114325 79608319
Abortion spontaneous 20.24 12.24 32 21712 29475 79693169
Rhabdomyolysis 20.20 12.24 68 21676 103063 79619581
Hypercholesterolaemia 20.09 12.24 28 21716 23067 79699577
Vertigo 19.67 12.24 52 21692 69030 79653614
Tooth injury 19.51 12.24 10 21734 2018 79720626
Wound 19.42 12.24 4 21740 116175 79606469
Onycholysis 19.25 12.24 10 21734 2073 79720571
Purpura 19.00 12.24 25 21719 19502 79703142
Type III immune complex mediated reaction 18.62 12.24 7 21737 671 79721973
Fixed eruption 18.56 12.24 11 21733 2943 79719701
Therapeutic product effect decreased 18.29 12.24 11 21733 163852 79558792
Miosis 18.20 12.24 22 21722 15767 79706877
Dyslipidaemia 18.19 12.24 19 21725 11614 79711030
Haemorrhagic erosive gastritis 18.04 12.24 7 21737 732 79721912
White blood cell count decreased 17.92 12.24 15 21729 188273 79534371
Arthrodesis 17.90 12.24 10 21734 2397 79720247
Eye infection 17.80 12.24 19 21725 11901 79710743
Pelvic pain 17.68 12.24 20 21724 13361 79709283
Tongue oedema 17.62 12.24 15 21729 7102 79715542
Urticaria thermal 17.53 12.24 6 21738 439 79722205
Dermatitis exfoliative 17.50 12.24 18 21726 10811 79711833
Disease prodromal stage 17.46 12.24 4 21740 65 79722579
Dermatitis exfoliative generalised 17.40 12.24 15 21729 7226 79715418
Guttate psoriasis 17.24 12.24 6 21738 461 79722183
Disease progression 17.16 12.24 15 21729 184347 79538297
Keratitis 17.03 12.24 12 21732 4310 79718334
Cerebral venous thrombosis 16.65 12.24 10 21734 2743 79719901
Poisoning deliberate 16.63 12.24 23 21721 18805 79703839
Urine oxalate increased 16.57 12.24 5 21739 244 79722400
Dyspepsia 16.51 12.24 66 21678 108621 79614023
Inflammatory bowel disease 16.27 12.24 13 21731 5638 79717006
Photosensitivity reaction 16.02 12.24 24 21720 21103 79701541
Hypersensitivity vasculitis 15.91 12.24 14 21730 6929 79715715
Urticaria chronic 15.72 12.24 6 21738 600 79722044
Myoglobin blood increased 15.41 12.24 10 21734 3141 79719503
Hyperoxaluria 15.28 12.24 5 21739 318 79722326
Systemic lupus erythematosus 15.19 12.24 7 21737 121142 79601502
Conjunctivitis allergic 15.16 12.24 8 21736 1712 79720932
Rash pustular 15.11 12.24 17 21727 11294 79711350
Cholangiocarcinoma 14.89 12.24 9 21735 2497 79720147
Pancreatitis acute 14.79 12.24 38 21706 49566 79673078
Cardiac pacemaker evaluation 14.73 12.24 4 21740 133 79722511
Serum amyloid A protein increased 14.67 12.24 5 21739 361 79722283
Alopecia areata 14.64 12.24 8 21736 1835 79720809
Upper respiratory tract infection bacterial 14.51 12.24 4 21740 141 79722503
Anaphylactic shock 14.48 12.24 31 21713 35965 79686679
Hyperlipasaemia 14.48 12.24 7 21737 1247 79721397
Arteriospasm coronary 14.31 12.24 13 21731 6703 79715941
Vascular cognitive impairment 14.18 12.24 3 21741 33 79722611
Sepsis 14.09 12.24 33 21711 269395 79453249
Drug dose titration not performed 14.03 12.24 6 21738 804 79721840
Dermatitis psoriasiform 13.99 12.24 9 21735 2785 79719859
Rhinitis allergic 13.99 12.24 17 21727 12252 79710392
Asthma 13.80 12.24 73 21671 135022 79587622
Altered state of consciousness 13.51 12.24 34 21710 43788 79678856
Retinopathy 13.50 12.24 10 21734 3881 79718763
Febrile neutropenia 13.15 12.24 27 21717 230972 79491672
Suicide attempt 13.11 12.24 51 21693 82881 79639763
Bunion operation 13.10 12.24 6 21738 946 79721698
Coronavirus infection 13.10 12.24 13 21731 7484 79715160
Feeding disorder 13.09 12.24 19 21725 16235 79706409
Lip oedema 13.02 12.24 12 21732 6304 79716340
Acute haemorrhagic oedema of infancy 12.51 12.24 3 21741 60 79722584
Pemphigoid 12.48 12.24 18 21726 15297 79707347
Drug level increased 12.48 12.24 31 21713 39620 79683024

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC R06AX27 RESPIRATORY SYSTEM
ANTIHISTAMINES FOR SYSTEMIC USE
ANTIHISTAMINES FOR SYSTEMIC USE
Other antihistamines for systemic use
FDA MoA N0000000190 Histamine H1 Receptor Antagonists
FDA EPC N0000175587 Histamine-1 Receptor Antagonist
MeSH PA D018678 Cholinergic Agents
MeSH PA D018680 Cholinergic Antagonists
MeSH PA D018494 Histamine Agents
MeSH PA D006633 Histamine Antagonists
MeSH PA D006634 Histamine H1 Antagonists
MeSH PA D039563 Histamine H1 Antagonists, Non-Sedating
MeSH PA D018377 Neurotransmitter Agents
CHEBI has role CHEBI:37955 H1 receptor antagonists
CHEBI has role CHEBI:48873 acetylcholine receptor antagonist
CHEBI has role CHEBI:49103 drug metabolites
CHEBI has role CHEBI:50857 anti-allergic drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Vasomotor rhinitis indication 8229003 DOID:4730
Allergic urticaria indication 40178009 DOID:10612
Allergic rhinitis indication 61582004
Nasal discharge indication 64531003
Nasal congestion indication 68235000
Sneezing indication 76067001
Common cold indication 82272006 DOID:10459
Chronic idiopathic urticaria indication 302162004
Seasonal allergic rhinitis indication 367498001
Allergic conjunctivitis indication 473460002 DOID:11204
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Coronary arteriosclerosis contraindication 53741008 DOID:3393
Diabetes mellitus contraindication 73211009 DOID:9351
Kidney disease contraindication 90708001 DOID:557
Disease of liver contraindication 235856003 DOID:409
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Angle-closure glaucoma contraindication 392291006 DOID:13550
Hypertensive urgency contraindication 443482000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.92 Basic
pKa2 2.48 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Histamine H1 receptor GPCR ANTAGONIST Ki 9.40 WOMBAT-PK CHEMBL
Sodium-dependent serotonin transporter Transporter Ki 6.91 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 5.96 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 8.03 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 7.55 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 7.80 DRUG MATRIX
5-hydroxytryptamine receptor 6 GPCR Ki 6.00 DRUG MATRIX
Alpha-2B adrenergic receptor GPCR Ki 6.01 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 6.19 DRUG MATRIX
Histamine H2 receptor GPCR Ki 5.97 DRUG MATRIX
Histamine H4 receptor GPCR IC50 4.80 CHEMBL
Muscarinic acetylcholine receptor M1 GPCR Ki 7.74 WOMBAT-PK
Muscarinic acetylcholine receptor M2 GPCR Ki 7.60 WOMBAT-PK
Muscarinic acetylcholine receptor M3 GPCR Ki 7.49 WOMBAT-PK
Muscarinic acetylcholine receptor M4 GPCR Ki 7.70 WOMBAT-PK
Muscarinic acetylcholine receptor M5 GPCR Ki 7.30 WOMBAT-PK
Sodium-dependent dopamine transporter Transporter Ki 5.51 DRUG MATRIX
Multidrug resistance protein 1 Transporter IC50 4.37 WOMBAT-PK
Alpha-1B adrenergic receptor GPCR Ki 5.70 DRUG MATRIX

External reference:

IDSource
4021292 VUID
N0000148729 NUI
D03693 KEGG_DRUG
275635 RXNORM
4021292 VANDF
C0908935 UMLSCUI
CHEBI:291342 CHEBI
CHEMBL1172 ChEMBL_ID
DB00967 DRUGBANK_ID
C121345 MESH_SUPPLEMENTAL_RECORD_UI
124087 PUBCHEM_CID
7157 IUPHAR_LIGAND_ID
7817 INN_ID
FVF865388R UNII
16243 MMSL
42606 MMSL
51632 MMSL
83662 MMSL
d04785 MMSL
009081 NDDF
134506008 SNOMEDCT_US
396015008 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Clarinex HUMAN PRESCRIPTION DRUG LABEL 1 21695-815 TABLET, FILM COATED 5 mg ORAL NDA 23 sections
Desloratadine HUMAN PRESCRIPTION DRUG LABEL 1 42291-240 TABLET 5 mg ORAL ANDA 26 sections
Clarinex HUMAN PRESCRIPTION DRUG LABEL 1 50090-0765 TABLET, FILM COATED 5 mg ORAL NDA 29 sections
Desloratadine HUMAN PRESCRIPTION DRUG LABEL 1 50090-3975 TABLET 5 mg ORAL ANDA 32 sections
Desloratadine HUMAN PRESCRIPTION DRUG LABEL 1 50090-3975 TABLET 5 mg ORAL ANDA 32 sections
DESLORATADINE HUMAN PRESCRIPTION DRUG LABEL 1 50090-4794 TABLET, FILM COATED 5 mg ORAL ANDA 27 sections
DESLORATADINE HUMAN PRESCRIPTION DRUG LABEL 1 50090-4794 TABLET, FILM COATED 5 mg ORAL ANDA 27 sections
Clarinex HUMAN PRESCRIPTION DRUG LABEL 1 54868-4624 TABLET, FILM COATED 5 mg ORAL NDA 12 sections
Clarinex-D 12 Hour HUMAN PRESCRIPTION DRUG LABEL 2 54868-5708 TABLET, EXTENDED RELEASE 2.50 mg ORAL NDA 29 sections
Desloratadine HUMAN PRESCRIPTION DRUG LABEL 1 55111-360 TABLET, ORALLY DISINTEGRATING 5 mg ORAL ANDA 26 sections
Desloratadine HUMAN PRESCRIPTION DRUG LABEL 1 55111-551 TABLET, ORALLY DISINTEGRATING 2.50 mg ORAL ANDA 26 sections
Desloratadine HUMAN PRESCRIPTION DRUG LABEL 1 62250-619 TABLET 5 mg ORAL ANDA 25 sections
Desloratadine HUMAN PRESCRIPTION DRUG LABEL 1 62250-619 TABLET 5 mg ORAL ANDA 25 sections
Desloratadine Human Prescription Drug Label 1 62756-523 TABLET, FILM COATED 5 mg ORAL ANDA 28 sections
DESLORATADINE HUMAN PRESCRIPTION DRUG LABEL 1 68180-153 TABLET, FILM COATED 5 mg ORAL ANDA 27 sections
DESLORATADINE HUMAN PRESCRIPTION DRUG LABEL 1 68180-153 TABLET, FILM COATED 5 mg ORAL ANDA 27 sections
Desloratadine HUMAN PRESCRIPTION DRUG LABEL 1 69543-107 TABLET 5 mg ORAL ANDA 29 sections
DESLORATADINE HUMAN PRESCRIPTION DRUG LABEL 1 71335-1000 TABLET, FILM COATED 5 mg ORAL ANDA 27 sections
Clarinex HUMAN PRESCRIPTION DRUG LABEL 1 78206-119 TABLET, FILM COATED 5 mg ORAL NDA 30 sections
Clarinex HUMAN PRESCRIPTION DRUG LABEL 1 78206-119 TABLET, FILM COATED 5 mg ORAL NDA 30 sections
Clarinex HUMAN PRESCRIPTION DRUG LABEL 1 78206-119 TABLET, FILM COATED 5 mg ORAL NDA 30 sections
CLARINEX-D 12 HOUR HUMAN PRESCRIPTION DRUG LABEL 2 78206-120 TABLET, EXTENDED RELEASE 2.50 mg ORAL NDA 29 sections
CLARINEX-D 12 HOUR HUMAN PRESCRIPTION DRUG LABEL 2 78206-120 TABLET, EXTENDED RELEASE 2.50 mg ORAL NDA 29 sections
CLARINEX-D 12 HOUR HUMAN PRESCRIPTION DRUG LABEL 2 78206-120 TABLET, EXTENDED RELEASE 2.50 mg ORAL NDA 29 sections
Clarinex HUMAN PRESCRIPTION DRUG LABEL 1 78206-188 TABLET, FILM COATED 5 mg ORAL NDA 30 sections